Skip to main content

29-09-2019 | Respiratory | Video

ERS 2019: Antifibrotic therapy improves long-term survival in IPF

Jürgen Behr discusses data from the INSIGHTS-IPF registry showing that, compared with patients who never received antifibrotic treatment for idiopathic pulmonary fibrosis, those who did experienced significantly better long-term survival (2:44).

Funding for independent interviews at ERS 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.